Clinicopathological features of patients with diffuse large B-cell lymphoma (N = 208)
| Clinicopathological feature | Frequency, N (%) |
| Sex | |
| Female | 96 (46.2) |
| Male | 112 (53.8) |
| Age | |
| Mean (SD) (years) | 63 (16) |
| Tumour stage | |
| I | 28 (17.7) |
| II | 50 (31.6) |
| III | 34 (21.5) |
| IV | 46 (29.1) |
| International Prognostic Index | |
| 0 | 2 (1.3) |
| 1 | 66 (43.4) |
| 2 | 29 (19.1) |
| 3 | 32 (21.1) |
| 4 | 23 (15.1) |
| B symptoms | |
| Absent | 86 (65.2) |
| Present | 46 (34.8) |
| Therapy | |
| None | 7 (4.6) |
| Radiotherapy | 1 (0.7) |
| Chemotherapy, mainly CHOP equivalents | 144 (94.7) |
| Death causes | |
| Dead with disease | 89 (78.1) |
| Secondary malignancies | 5 (4.4) |
| Cardiovascular | 14 (12.2) |
| Other (trauma, infection) | 6 (5.3) |
| 1-year survival | |
| Rate | 67.6% |
| 5-year survival | |
| Rate | 55.5% |
| Follow-up time | |
| Mean, range (months) | 41, 1 to 218 |
CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone.